Role of liver stiffness measurements in patients who develop hepatocellular carcinoma after clearance of the hepatitis C virus

Yoshinori Gyotoku1 · Ryosaku Shirahashi1 · Toshikuni Suda1 · Masaya Tamano1

Received: 2 November 2021 / Accepted: 28 November 2021 / Published online: 7 February 2022
© The Author(s) 2022

Abstract

Purpose To measure changes in liver stiffness over time due to direct-acting antiviral (DAA) therapy in hepatitis C patients using shear wave elastography (SWE).

Methods Patients with hepatitis C treated with DAA therapy in a university medical center between July 2015 and April 2020 were evaluated. Shear wave velocity (Vs) of the liver was measured using SWE. Alanine aminotransferase (ALT), platelet count, and α-fetoprotein (AFP) were measured at the same time, and the FIB-4 index was estimated. Absence of hepatocellular carcinoma was confirmed at baseline and end of therapy. Imaging was then performed every 6 months. Patient characteristics were compared between patients who did and did not develop carcinoma.

Results The mean age of the 229 patients (93 men) was 65.6 years. Eight patients developed carcinoma during follow-up (mean 32.6 ± 19.5 months). Significant differences were found between the groups in terms of AFP, platelet count, and Fib-4 index at baseline; the pre-treatment data had the best relationship with hepatocarcinogenesis. Mean Vs decreased significantly during DAA therapy, and then decreased further. Liver stiffness 6 months after treatment ended had the best relationship with hepatocarcinogenesis.

Conclusion In patients with a sustained virological response, risk of developing cancer can be predicted by measuring Vs approximately 6 months after treatment.

Keywords  Hepatitis C · hepatocellular carcinoma · Direct-acting antiviral therapy · Shear wave elastography

Introduction

Significant advances have been made in the treatment of hepatitis C with the advent of direct-acting antiviral agents (DAAs). DAA therapy has milder side effects than IFN therapy, and there is a high rate of sustained virological response (SVR) [1–5]. When SVR is achieved with DAA therapy, cancer inhibition similar to that with IFN therapy is seen [6–8]. High ALT and AFP values and low platelet counts are reported to be risk factors for cancer after SVR [9], but they are analyzed based on pre- and post-treatment clinical data.

At our hospital, we see many patients in whom SVR was achieved with DAA therapy at other institutions. In such cases, since we do not know the blood test findings at the start and end of DAA therapy, it is a struggle to infer the cancer risk of the patient.

Shear wave elastography (SWE) is a technique that is used to assess stiffness of the liver by measuring the propagation velocity of shear waves (Vs) generated in liver tissue. Vs measurements with SWE are effective in diagnosing liver fibrosis in patients with hepatitis C [10].

A previous study showed that, in patients with hepatitis C, measurements of liver stiffness by SWE were higher in the naïve group compared to the SVR group, probably due to hepatitis activity [11]. In addition, compared with pre-treatment levels, an improvement in liver stiffness was reported in patients with hepatitis C who achieved SVR by treatment with DAAs [12]. Further, this improvement in liver stiffness was observed to be more noticeable in patients with hepatitis C with advanced fibrosis [13, 14].

In this study, the focus was on liver stiffness measured by SWE that changes over time due to DAA therapy in patients with hepatitis C. Hepatitis C patients in whom SVR is
achieved will continue to increase in the future, and if liver stiffness after the end of DAA therapy were shown to affect carcinogenesis, it would contribute greatly to screening these patients for hepatocellular carcinoma (HCC).

**Patients and methods**

**Patients**

The subjects included 355 patients at a university medical center who were diagnosed with hepatitis C and treated with DAAs between July 2015 and April 2020. Patients with autoimmune disease, chronic heart disease, collagen disease, decompensated liver cirrhosis, or HCC were excluded from the study. Patients with a history of HCC were also not included in this study. Similarly, patients diagnosed with fatty liver on ultrasonography or those with chronic alcohol consumption history (alcohol intake ≥ 20 g/day) were also excluded.

**Shear wave velocity measurements**

A LOGIQ E9 multi-purpose ultrasound system (GE Healthcare, Milwaukee, WI, USA) was used to measure Vs (m/s) by SWE. Visualization of segment 5 of the liver was performed through an intercostal space. Patients abduced the right arm in the supine position on a bed. Measurements of Vs were performed while patients held their breath. The region of interest (ROI) was fixed 1–2 cm under the surface of the liver. Adjustments were made to the system so that sample volume depth was less than or equal to 4 cm. Vs measurements were calculated automatically by the system, and results were considered reliable when the measurement success rate was > 80% from ten successful shots.

For all patients, the duration of DAA treatment was 8–12 weeks. SWE was performed before initiating treatment (baseline), at the end of treatment (EOT), 12 weeks after EOT (follow-up 12), and 24 weeks after EOT (follow-up 24).

**Clinical parameters**

The clinical parameters that were obtained on the same day that SWE was performed were compared. In addition to Vs, the clinical parameters measured included α-fetoprotein (AFP), alanine aminotransferase (ALT), and platelet count. Parameter measurements were conducted on the same days as SWE. The fibrosis-4 (FIB-4) index for liver fibrosis was estimated using patient age and the values obtained for ALT, serum aspartate transaminase (AST), and platelet count.

**Comparison of non-carcinogenic and carcinogenic groups**

In all of the patients, it was confirmed on abdominal ultrasound, CT scan, or Gd-EOB-DTPA-enhanced MRI (EOB-MRI) that there were no HCC complications at baseline and EOT. Abdominal ultrasound was performed every 6 months after the end of therapy, and if a liver tumor was seen, contrast CT or EOB-MRI was performed.

Patient characteristics at the start of treatment were compared between the non-carcinogenic group, in which HCC was not seen during the observation period, and the carcinogenic group, in which HCC was seen during the observation period. In addition, factors for which significant differences were seen in data at the start of treatment were confirmed at EOT, follow-up 12, and follow-up 24.

**Statistical analysis**

The data for clinical parameters and liver stiffness are expressed as means ± standard deviation (SD). A paired Wilcoxon test was used to compare each parameter before and after starting treatment. The diagnostic performances of liver stiffness and other clinical parameters for predicting the presence of HCC were evaluated using receiver operating characteristic (ROC) curve analyses. The area under the ROC curve (AUROC) was used to assess diagnostic accuracy.

**Results**

**Patient characteristics at the start of treatment**

A total of 355 patients with hepatitis C were recruited for the study. After excluding 21 patients for whom Vs was not measured all three times, 14 patients lost to follow-up, and 91 patients for whom the observation period was less than 6 months, the investigation included 229 cases (Fig. 1).

Table 1 shows patient characteristics at the start of treatment. The mean age was 65.6 years, 93 were men, and 136 were women. The DAAs selected for treating these 229 patients were sofosbuvir/ribavirin in 71 patients, SOF/ledipasvir (LDV) in 58 patients, ombitasvir/paritaprevir/ritonavir in 41 patients, elbasvir/pibrentasvir in 30 patients, glecaprevir/pibrentasvir in 24 patients, ombitasvir/paritaprevir/ritonavir/ribavirin in three patients, and daclatasvir/asunaprevir in two patients. A total of 42 patients had previously received interferon (IFN) therapy. The DAA treatment period was 8–12 weeks, depending on the type of drug.
Mean ALT was 55.5 IU/L, showing a moderate increase. In contrast, total bilirubin, albumin, platelet count, and prothrombin activity were within the standard range. Mean AFP was 9.49 ng/ml, mean Vs was 1.58 m/s, and mean Fib-4 index was 3.49.

The mean observation period for the 229 patients was 32.6 ± 19.5 (6–74) months, and hepatocellular carcinoma was seen in eight of the 229 patients.

**Patient characteristics in non-carcinogenic group and carcinogenic group**

Table 2 shows the characteristics of the 229 patients in the non-carcinogenic group and the eight patients in the carcinogenic group. There was a trend toward higher age in the carcinogenic group compared with the non-carcinogenic group, but the difference was not significant (p = 0.1742). Similarly, there was a trend toward more men in the carcinogenic group, but no significant difference was seen (p = 0.5820).

Compared with the non-carcinogenic group, ALT, AFP, Vs, and Fib-4 index were significantly higher in the carcinogenic group (p = 0.0095, p = 0.0003, p = 0.0036, and p = 0.0006, respectively). The platelet count was significantly lower in the carcinogenic group than in the non-carcinogenic group, but the differences were not significant (p = 0.0744 and p = 0.1444, respectively). The mean time from the end of treatment to the development of cancer was 21.3 months.

**Clinical parameters in the non-carcinogenic group and carcinogenic group**

ALT, platelet count, AFP, VS, and Fib-4 index are shown in Table 3 for the carcinogenic and non-carcinogenic groups. At EOT, significant differences were seen in all five parameters. Similar to the results at EOT, significant differences were seen in four parameters all but ALT at follow-up 12 and 24.

**Changes in Vs from baseline to follow-up 24**

Figure 2 shows the changes in Vs from baseline to follow-up 24. Vs measurements decreased over time, measuring 1.59 ± 0.27 m/s at baseline, 1.50 ± 0.26 m/s at EOT, 1.45 ± 0.24 m/s at follow-up 12, and 1.43 ± 0.02 m/s at follow-up 24 (p < 0.0001, p = 0.0992, and p = 0.0491, respectively).

**Eight carcinogenic patients**

We show the list of eight carcinogenic patients in Table 4. Only one patient (No. 7) had two tumors, while the other seven patients had a single tumor. All eight patients were treated and had a good clinical course.
Receiver operating characteristic curve analyses

The ROC curves for Vs, ALT, AFP, Fib-4 index, and platelet count at each time point are shown in Fig. 3. The AUROC of Vs was 0.80 at baseline, 0.75 at EOT, 0.72 at follow-up 12, and 0.86 at follow-up 24. Thus, it was the largest at follow-up 24. Similarly, that of ALT was 0.79 at baseline, 0.63 at EOT, 0.64 at follow-up 12, and 0.57 at follow-up 24; that of AFP was 0.91 at baseline, 0.88 at EOT, 0.87 at follow-up 12, and 0.85 at follow-up 24; that of Fib-4 index was 0.87 at baseline, 0.78 at EOT, 0.84 at follow-up 12, and 0.83 at follow-up 24; and that of platelet count was 0.81

### Table 2 Patient characteristics in the non-carcinogenic group and carcinogenic group at baseline

|                      | Non-carcinogenic group (n = 211) | Carcinogenic group (n = 8) | p value |
|----------------------|----------------------------------|---------------------------|---------|
| Age (y)              | 65.3 ± 12.7 (21–84)              | 72.1 ± 6.8 (64–84)        | 0.1742  |
| Sex (male/female)    | 89/132                           | 4/4                       | 0.5820  |
| ALT (IU/L)           | 54.2 ± 45.9 (6–426)              | 99.3 ± 56.4 (37–187)      | 0.0095  |
| GGT (IU/L)           | 49.2 ± 56.0 (9–575)              | 57.3 ± 28.3 (33–111)      | 0.1293  |
| Total bilirubin (mg/dl) | 0.84 ± 0.63 (0.1–9)      | 1.01 ± 0.50 (0.7–2.1)    | 0.1980  |
| Alb (g/dl)           | 4.2 ± 0.4 (2.9–5.3)              | 3.9 ± 0.3 (3.5–4.4)       | 0.0744  |
| WBC (10⁹/mm³)        | 5.12 ± 1.70 (2–12.2)             | 4.59 ± 1.26 (2.5–5.7)     | 0.7181  |
| Hb (g/dl)            | 13.7 ± 1.50 (10–18.1)            | 14.0 ± 1.13 (12.2–15.7)   | 0.6602  |
| Plt (10⁴/mm³)        | 17.0 ± 6.2 (4.1–36.1)            | 11.3 ± 2.6 (8.6–15.2)     | 0.0059  |
| PT% (%)              | 98.8 ± 16.7 (27–147)             | 90.7 ± 11.8 (78–106)      | 0.1444  |
| AFP (ng/ml)          | 8.0 ± 14.4 (0.6–140.5)           | 51.5 ± 52.5 (8.9–139.9)   | 0.0003  |
| Vs (m/s)             | 1.58 ± 0.26 (1.03–2.56)          | 1.86 ± 0.20 (1.52–2.26)   | 0.0036  |
| Fib-4 index          | 3.38 ± 2.71 (0.30–19.11)         | 6.87 ± 2.40 (3.43–10.13)  | 0.0006  |
| Observation period (M) | 33.0 ± 19.4 (6–74)       | 21.3 ± 17.6 (6–58)       | 0.1193  |

ALT alanine aminotransferase, GGT γ-glutamyltransferase, WBC white cell count, Plt platelet count, Alb serum albumin, PT% prothrombin time, AFP alpha-fetoprotein, Vs shear wave velocity, Fib-4 index fibrosis-4 index

### Table 3 Clinical parameters in the non-carcinogenic group and carcinogenic group

|                      | Non-carcinogenic group (n = 211) | Carcinogenic group (n = 8) | p value |
|----------------------|----------------------------------|---------------------------|---------|
| ALT (U/L) EOT        | 54.2 ± 45.9 (6–426)              | 99.3 ± 56.4 (37–187)      | 0.0095  |
| Follow-up 12         | 19.8 ± 14.4 (7–95)               | 32.8 ± 37.4 (12–122)      | 0.2271  |
| Follow-up 24         | 17.2 ± 11.5 (4–123)              | 24.7 ± 20.4 (8–64)        | 0.2495  |
| Plt (10⁴/mm³) EOT    | 17.0 ± 6.2 (4.1–36.1)            | 11.3 ± 2.6 (8.6–15.2)     | 0.0059  |
| Follow-up 12         | 18.5 ± 7.0 (3.6–47.2)            | 13.3 ± 4.6 (7.9–20.7)     | 0.0261  |
| Follow-up 24         | 18.2 ± 6.5 (2.9–38.6)            | 13.6 ± 3.6 (9.7–19.6)     | 0.0469  |
| AFP (ng/ml) EOT      | 8.0 ± 14.4 (0.6–140.5)           | 51.0 ± 60.6 (8.9–139.9)   | 0.0003  |
| Follow-up 12         | 4.1 ± 2.8 (0.6–14.8)             | 9.0 ± 4.5 (5–17.4)        | 0.0007  |
| Follow-up 24         | 3.8 ± 2.5 (0.6–18.7)             | 8.8 ± 5.3 (3.7–16.5)      | 0.0019  |
| Vs (m/s) EOT         | 1.58 ± 0.26 (1.03–2.56)          | 1.75 ± 0.22 (1.35–2.15)   | 0.0036  |
| Follow-up 12         | 1.49 ± 0.25 (1.01–2.25)          | 1.66 ± 0.15 (1.49–1.87)   | 0.0184  |
| Follow-up 24         | 1.44 ± 0.24 (0.95–2.25)          | 1.69 ± 0.121 (1.50–1.95)  | 0.0308  |
| Fib-4 index EOT      | 3.38 ± 2.71 (0.30–19.11)         | 6.87 ± 2.40 (3.43–10.13)  | 0.0006  |
| Follow-up 12         | 2.55 ± 1.914 (0.28–12.68)        | 4.49 ± 2.72 (1.64–10.44)  | 0.0067  |
| Follow-up 24         | 2.53 ± 1.75 (0.01–15.52)         | 4.41 ± 1.84 (2.44–7.55)   | 0.0048  |

ALT alanine aminotransferase, Plt platelet count, AFP alpha-fetoprotein, Vs shear wave velocity, Fib-4 index fibrosis-4 index
at baseline, 0.73 at EOT, 0.74 at follow-up 12, and 0.79 at follow-up 24. The AUROC was the largest at baseline for all parameters.

Discussion

Hepatitis C patients are reported to have sustained changes in protein expression due to epigenetic changes in hepatocytes even after SVR, and these changes contribute to the development of liver cancer [15]. Therefore, identification of carcinogenic risk factors after SVR with DAA therapy and the creation of surveillance systems are issues that need to be addressed.

Advanced age, progression of hepatic fibrosis, male sex, and AFP level have been shown to be independent risk factors for hepatocellular carcinogenesis in hepatitis C patients [16–19]. In this study, although there was no significant difference in age or sex at baseline between the carcinogenic and non-carcinogenic groups, this was likely due to the small number of people in the carcinogenic group. Significant differences were shown between the groups in terms of AFP level, platelet count, and Fib-4 index, which are indicators of hepatic fibrosis, at baseline.

A previous study using SWE reported that Vs was approximately 1.2 m/s in healthy livers. Although the mean Vs at baseline in this study was 1.56 ± 0.26 m/s, Vs decreased significantly to 1.50 ± 0.26 m/s over the 8–12 weeks of DAA therapy. Vs at follow-up 12 and 24 showed significant decreases to 1.45 ± 0.24 m/s and 1.43 ± 0.24 m/s, respectively.

Vs decreased over time from baseline to follow-up 24, but it did not reach the level found in healthy livers. When SVR is achieved in hepatitis C patients, it is reported to take 3 years for histological improvement in fibrosis [20]. Liver stiffness, inferred using Vs, is influenced not only by the degree of liver fibrosis but also by the degree of necroinflammatory activity [21, 22]. Both inflammation and fibrosis of the liver contribute to baseline Vs, and Vs is thought to more accurately show fibrosis of the liver with the passage of time at EOT, follow-up 12, and follow-up 24.

As shown in Table 2, a comparison of patient characteristics at baseline showed higher ALT, AFP, Vs, and Fib-4 index, and a lower platelet count, in the carcinogenic group than in the non-carcinogenic group. This shows that liver inflammation, regeneration, and fibrosis at baseline contribute to carcinogenesis. As shown in Table 3, comparisons of these five parameters at each time point showed significant differences in all but ALT.

Investigation of the AUROC of ALT, AFP, Vs, Fib-4 index, and platelet count at each time point revealed that the AUROC was the largest at baseline for ALT, AFP, Fib-4 index, and platelet count. In contrast, the AUROC was the largest at follow-up 24 for Vs.

These results show that, for ALT, AFP, Fib-4 index, and platelet count, pre-treatment data have the best relationship with hepatocarcinogenesis, whereas liver stiffness measured

Table 4 List of eight carcinogenic patients

| No | Sex | Age (years) | AFP (ng/ml) | Vs (m/s) | Tumor size (mm) |
|----|-----|-------------|-------------|----------|----------------|
|    |     |             |             | EOT      | Follow-up 12   | Follow-up 24   |
| 1  | Male| 74          | 13.7        | 1.81     | 1.86           | 1.95           | 30            |
| 2  | Female| 78        | 137.5       | 2.15     | 1.87           | 1.65           | 20            |
| 3  | Female| 71         | 9.5         | 1.71     | 1.55           | 1.50           | 10            |
| 4  | Male | 64          | 12.3        | 1.55     | 1.49           | 1.53           | 12            |
| 5  | Female| 84         | 8.9         | 1.71     | 1.63           | 1.87           | 20            |
| 6  | Female| 65         | 35.3        | 1.87     | 1.67           | 1.92           | 50            |
| 7  | Male | 67          | 54.5        | 1.35     | 1.45           | 1.35           | 10            |
| 8  | Male | 74          | 139.9       | 1.85     | 1.79           | 1.76           | 15            |

*AFP* alpha-fetoprotein, *Vs* shear wave velocity
Fig. 3 Receiver operating characteristic curves for Vs, ALT, AFP, Fib-4 index, and platelet count at each time point. The area under the receiver operating characteristic curve (AUROC) of Vs is 0.80317 at baseline, 0.74548 at EOT, 0.72147 at follow-up 12, and 0.86041 at follow-up 24; the largest at follow-up 24. Similarly, that of ALT is 0.78798 at baseline, 0.62557 at EOT, 0.63789 at follow-up 12, and 0.56628 at follow-up 24; that of AFP is 0.90746 at baseline, 0.87760 at EOT, 0.87261 at follow-up 12, and 0.84929 at follow-up 24; that of Fib-4 index is 0.87395 at baseline, 0.78252 at EOT, 0.83849 at follow-up 12, and 0.82956 at follow-up 24; and that of platelet count is 0.80608 at baseline, 0.73162 at EOT, 0.73840 at follow-up 12, and 0.78640 at follow-up 24. The AUROC is the largest at baseline for all parameters. Baseline before starting treatment, EOT end of treatment, follow-up 12 12 weeks after EOT, follow-up 24 4 weeks after EOT.

Conclusions

This study demonstrated that, when an SVR patient whose pre- and post-treatment data are not known presents for initial examination, the patient’s risk of developing cancer can be predicted by measuring Vs approximately 6 months after treatment. The number of hepatitis C patients achieving SVR will continue to increase in the coming years, and this result will contribute greatly to HCC screening in these patients.

Acknowledgements

We would like to thank the institutions that participated in the working group and everyone who helped collect clinical data.

Author contributions

YG and RS conceptualized and designed the study, collected data, carried out the initial analysis, and drafted the initial manuscript. TS and MT coordinated and supervised data collection.
and critically reviewed the manuscript for important intellectual content. All the authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Declarations

Conflict of interest Yoshinori Gyotoku, Ryosaku Shirahasi, Toshikuni Suda, and Masaya Tamano have no financial relationships relevant to this article to disclose.

Ethical statements All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. The Local Ethics Committee confirmed this study and approved it. Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient gave informed consent to treatment. For full disclosure, the details of this retrospective, observational study were published on the website of the medical center.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Ramos H, Linares P, Badia E, et al. Interferon-free treatments in patients with hepatitis C genotype 1–4 infections in a real-world setting. World J Gastrointest Pharmacol Ther. 2017;8:137–46.
2. Kanda T, Yasui S, Nakamura M, et al. Real-world experiences with the combination treatment of ledipasvir plus sofosbuvir for 12 weeks in HCV genotype 1-infected Japanese patients: achievement of a sustained virological response in previous users of peginterferon plus ribavirin with HCV NS3/4A inhibitors. Int J Mol Sci. 2017;18:906.
3. Flisiak R, Lucejko M, Mazur W, et al. Effectiveness and safety of ledipasvir/sofosbuvir+/-ribavirin in the treatment of HCV infection: The real-world HARVEST study. Adv Med Sci. 2017;62:387–92.
4. Virabhak S, Yasui K, Yamazaki K, et al. Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naive and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan. J Med Econ. 2016;19:1144–56.
5. Kumada H, Chayama K, Rodrigues I Jr, et al. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology. 2015;62:1037–46.
6. Li DK, Ren Y, Fierer DS, et al. The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study. Hepatology. 2018;67:2244–53.
7. Innes H, Barclay ST, Hayes PC, et al. The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen. J Hepatol. 2018;68:646–54.
8. Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2017;68:25–32.
9. Asahina Y, Tsuichi K, Nishimura T, et al. alpha-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology. 2013;58:1253–62.
10. Tada T, Kumdada T, Toyoda H, et al. Utility of real-time shear wave elastography for assessing liver fibrosis in patients with chronic hepatitis C infection without cirrhosis: Comparison of liver fibrosis indices. Hepatol Res. 2015;45:E122–9.
11. Suda T, Okawa O, Masaoka R, et al. Shear wave elastography in hepatitis C patients before and after antiviral therapy. World J Hepatol. 2017;9:64–8.
12. Pons M, Santos B, Simon-Talero M, et al. Rapid liver and spleen stiffness improvement in compensated advanced chronic liver disease patients treated with oral antivirals. Therap Adv Gastroenterol. 2017;10:619–29.
13. Ogasawara N, Kobayashi M, Akuta N, et al. Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b. J Med Virol. 2018;90:313–9.
14. Tada T, Kumdada T, Toyoda H, et al. Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. J Gastroenterol Hepatol. 2017;32:1982–8.
15. Hamdane N, Jübling F, Crouchet E, et al. HCV-induced epigenetic changes associated with liver cancer risk persist after sustained virologic response. Gastroenterology. 2019;156:2313–2329.e7.
16. Nagata H, Nakagawa M, Ashina Y, et al. Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol. 2017;67:933–9.
17. Cardoso AC, Touchardi R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol. 2010;52:652–7.
18. Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 1999;29:1124–30.
19. Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology. 1998;27:1394–402.
20. Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med. 1997;127:875–81.
21. Arena U, Vizzutti F, Corti G, et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology. 2008;47:380–4.
22. Coco B, Oliveri F, Maina AM, et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat. 2007;14:360–9.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.